{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:15:52Z","timestamp":1791303352772,"version":"4.1.0"},"reference-count":40,"publisher":"Academy of Managed Care Pharmacy","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.18553\/jmcp.2020.26.12.1494","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T11:56:26Z","timestamp":1606737386000},"page":"1494-1504","source":"Crossref","is-referenced-by-count":5,"title":["Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients"],"prefix":"10.18553","volume":"26","author":[{"given":"Donna R","family":"Rivera","sequence":"first","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Enewold","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Health Care Delivery Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Barrett","sequence":"additional","affiliation":[{"name":"Information Management Services, Calverton, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Banegas","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K","family":"Filipski","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Epidemiology and Genomics Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N","family":"Freedman","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Epidemiology and Genomics Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K","family":"Lam","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Mariotto","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Rockville, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"R1","unstructured":"Howlader NA, Krapcho M, Miller D, et al. eds. SEER Cancer Statistics Review, 1975-2013. National Cancer Institute. April 2016. Accessed October 28, 2020. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"R5","unstructured":"GLEEVEC (imatinib mesylate) tablets for oral use. Novartis Pharma. 2001. Accessed October 28, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.004"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4184"},{"issue":"15","key":"R9","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.32137","volume":"125","author":"Kenzik KM","year":"2019","journal-title":"Cancer"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.014639"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000496"},{"key":"R12","first-page":"Iv","volume":"40","author":"Warren JL","year":"2002","journal-title":"Med Care"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000693"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24887"},{"key":"R15","unstructured":"Pope G, Kautter J, Ingber MJ, Freeman S, Sekar R, Newhart C. Evaluation of the CMS-HCC risk adjustment model. Final report. Centers for Medicare & Medicaid Services. March 2011. Accessed October 28, 2020. https:\/\/www.cms.gov\/Medicare\/Health-Plans\/MedicareAdvtgSpecRateStats\/downloads\/Evaluation_Risk_Adj_Model_2011.pdf"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-245"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.170"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6039-9"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"issue":"348","key":"R21","first-page":"994","volume":"2003","author":"O\u2019Brien SG","journal-title":"N Engl J Med"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094045"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.07.016"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23330"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2041-0"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.008"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0306-5"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.03.018"},{"issue":"143","key":"R31","first-page":"137","volume":"26","author":"Alagiakrishnan K","year":"2018","journal-title":"Discov Med"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.07.004"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"R35","unstructured":"Cubanski J, Neuman T. Assessing drug price increases in Medicare Part D and the implications of inflation limits. Kaiser Family Foundation. October 18, 2019. Accessed October 29, 2020. https:\/\/www.kff.org\/medicare\/issue-brief\/assessing-drug-price-increases-in-medicare-part-d-and-the-implications-of-inflation-limits\/"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019737"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4893"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7303"},{"issue":"1","key":"R41","first-page":"39","volume":"79","author":"Sloan C","year":"2018","journal-title":"N C Med J"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.5"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:09:14Z","timestamp":1697267354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2020.26.12.1494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.18553\/jmcp.2020.26.12.1494"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2020.26.12.1494","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}